AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31206400
Drug: High-fiber DASH
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber DASH diet (32 g/d)
Trial: 30055723
Drug: Narrative-based language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative-based language intervention (NBLI) group therapy
Trial: 30055723
Drug: Conventional speech
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional speech therapy (CST)
Trial: 27022997
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (MI) group - healthy nutrition educational program in addition to a healthy daily meal
Trial: 27022997
Drug: Environmental intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Environmental intervention group - received a healthy daily meal
Trial: 25034548
Drug: Concurrent physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent physical training program (CPTP) consisting of running training in the Fatmax intensity zone and strength training (squats and bench presses); three 40‐minute sessions a week for 24 weeks
Trial: 16289514
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg intravenous (i.v.) or oral
Trial: 340137
Drug: salsalate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salsalate (3 g/day)
Trial: 7133973
Drug: indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin (75 mg/day)
Trial: 30301829
Drug: AR‐V7+ patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR‐V7+ patients receiving taxane therapy (docetaxel or cabazitaxel)
Trial: 30301829
Drug: ARv567es+ patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARv567es+ patients receiving taxane therapy
Trial: 21775562
Drug: Fish-oil-based lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil-based lipid emulsion (FOLE) at a dose of 1 g · kg(‐1) · d(‐1) for ≥1 month
Trial: 17383291
Drug: Carvedilol (up-titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (up-titrated to 25 mg BID)
Trial: 17383291
Drug: Enalapril (up-titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (up-titrated to 20 mg BID) and spironolactone (25 mg QD)
Trial: 8111946
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (5% with Tegaderm)
Trial: 1098397
Drug: Practolol (beta-1-blocker)
RxNorm normalized name: practolol
DrugBank: Practolol (DB01297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (beta-1-blocker)
Trial: 1098397
Drug: Practolol +
RxNorm normalized name: practolol
DrugBank: Practolol (DB01297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol + Salbutamol (beta-2-stimulating drug)
Trial: 31711707
Drug: KP-10 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KP-10 (5 μg/kg body weight), injected once weekly for one month
Trial: 30927509
Drug: Telephone consultations
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone consultations with physiotherapists involving education, advice, and prescription of a strengthening and physical activity program over 26 weeks.
Trial: 26416154
Drug: Brimonidine gel
RxNorm normalized name: brimonidine Topical Gel
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine gel 0.33%
Trial: 24249434
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mitiglinide and sitagliptin
Trial: 16460701
Drug: 3D surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D surface models of the CC
Trial: 16460701
Drug: Statistical maps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical maps of the CC
Trial: 15257792
Drug: Quinine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine treatment at 10 mg/kg thrice daily for 7 days
Trial: 15257792
Drug: Quinine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine treatment at 10 mg/kg twice daily for 7 days
Trial: 15257792
Drug: Quinine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine treatment at 15 mg/kg once daily for 7 days
Trial: 11398082
Drug: APC 366
RxNorm normalized name: Recombinant human activated protein C (rH-APC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APC 366 (5 mg)
Trial: 2169077
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injection once daily)
Trial: 29557230
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vaginal progesterone effervescent tablet daily (Group A)
Trial: 29557230
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg IM 17‐OHPC weekly (Group B)
Trial: 27040576
Drug: Hyperuricemia (UA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperuricemia (UA >7 mg/dl in men and >6 mg/dl in women)
Trial: 27040576
Drug: Normouricemic patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normouricemic patients (UA ≤7 mg/dl in men and ≤6 mg/dl in women)
Trial: 18508198
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of ultrasound to the right supraspinatus trigger point
Trial: 15623811
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol therapy (0.05, 0.10, 0.15, and 0.20 mg/d for 4 consecutive days)
Trial: 14504183
Drug: Low-dose AdVEGF121
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose AdVEGF121 (4x10^9 PU)
Trial: 14504183
Drug: High-dose AdVEGF121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AdVEGF121 (4x10^10 PU)
Trial: 14504183
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Low-dose, High-dose, Placebo)
Trial: 2499174
Drug: Lactase tablet
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase tablet (LT)
Trial: 336322
Drug: MK-231 (Sulindac),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-231 (Sulindac), 200-400 mg daily
Trial: 29307157
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation therapy program (exercise intervention) for 8 weeks, including compensatory training, enhancement of visual and somatosensory function, and balance training.
Trial: 16461847
Drug: HT-treated (ramipril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT-treated (ramipril, 5 to 10 mg/d during 3 months; n=12)
Trial: 15268921
Drug: levodopa infusion
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: levodopa infusion
Trial: 24967366
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II - parents provided with detailed information about anesthesia administration, drugs used, side effects, and complications.
Trial: 20458201
Drug: Integrated motivational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated motivational interviewing and cognitive behavior therapy
Trial: 16186374
Drug: Ruboxistaurin (RBX)
RxNorm normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin (RBX) 4, 16, or 32 mg/d
Trial: 1665400
Drug: Hep‐B Vax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hep‐B Vax vaccine administered at 0, 1, and 6 months after birth (5 or 2.5 micrograms in pilot study, 5 micrograms in main study)
Trial: 1665400
Drug: Hep‐B Vax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hep‐B Vax vaccine
Trial: 27025835
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) 60 mg + Sofosbuvir (SOF) 400 mg for 12 weeks
Trial: 22089462
Drug: Non-adjuvanted influenza
RxNorm normalized name: Influenza, adjuvanted, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted influenza A H1N1/2009 vaccine
Trial: 20538134
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg) plus Simvastatin (40 mg)
Trial: 17933700
Drug: Indinavir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 600 mg BID + Ritonavir 100 mg BID
Trial: 17933700
Drug: Indinavir 400
RxNorm normalized name: indinavir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 400 mg BID + Ritonavir 100 mg BID
Trial: 15686782
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with anti‐anginal drugs (not specified which drugs or dosages)
Trial: 15686782
Drug: Invasive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatments (not specified)
Trial: 9867093
Drug: Fructose-sorbitol (F-S)
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose-sorbitol (F-S) mixture (25 g fructose and 5 g sorbitol)
Trial: 1648488
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg molsidomine
Trial: 2633458
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg isosorbide dinitrate retard
Trial: 22674141
Drug: Eltrombopag 12.5
RxNorm normalized name: eltrombopag 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 12.5 mg once daily for 2 weeks
Trial: 22674141
Drug: Eltrombopag 25
RxNorm normalized name: eltrombopag 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 25 mg once daily for 2 weeks
Trial: 22674141
Drug: Eltrombopag 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 37.5 mg once daily for 2 weeks
Trial: 20953062
Drug: Atorvastatin (80mg/day)
RxNorm normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80mg/day) for 3 weeks
Trial: 17403003
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (20 mg) every 5 min
Trial: 12070543
Drug: Metformin (850mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850mg twice daily) plus Clomiphene citrate (50mg, increasing to 200mg)
Trial: 7670451
Drug: Lactate supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate supplementation (10 g of lactate as calcium, sodium, and potassium salts, twice a day for 3 weeks)
Trial: 7670451
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, twice a day for 3 weeks)
Trial: 2073113
Drug: Aerosolized rimantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized rimantadine at 20 micrograms/liter of air for 12 hours daily for 3 days
Trial: 2073113
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of rimantadine at 200 mg
Trial: 28435222
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg dexmedetomidine (BD group)
Trial: 28435222
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL 0.9% normal saline (BN group)
Trial: 23939663
Drug: Adapted simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapted simvastatin doses (ranging from 25 to 80 mg)
Trial: 23939663
Drug: Standard simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard simvastatin dose (40 mg)
Trial: 23939663
Drug: Low adapted
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low adapted simvastatin dose (12 mg) during CYP3A inhibition with ritonavir
Trial: 20933491
Drug: DEC plus
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC plus albendazole (DEC/ALB) combination
Trial: 8690148
Drug: Hyperinsulinemic hypoglycemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic hypoglycemia (2.6 +/- 0.1 mmol/l, 47 +/- 1 mg/dl)
Trial: 8690148
Drug: Hyperinsulinemic euglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic euglycemia (4.8 +/- 0.1 mmol/l, 86 +/- 5 mg/dl)
Trial: 8690148
Drug: Stepped hypoglycemic
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepped hypoglycemic clamps (4.7, 4.2, 3.6, 3.0, 2.8, 2.5, and 2.2 mmol/l)
Trial: 20831134
Drug: 5000 ppm
RxNorm normalized name: Sodium Fluoride 5000 PPM
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5000 ppm sodium fluoride (F‐gel)
Trial: 17506855
Drug: Cetirizine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 50 mg (healthy volunteers)
Trial: 11894723
Drug: Monophasic combination
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic combination of EE and GST
Trial: 11894723
Drug: Low-dose OCs
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OCs containing newer gonane progestogens
Trial: 7859140
Drug: Thymopentin, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin, 50 mg subcutaneously 3 times per week
Trial: 1777589
Drug: Long-term antibiotic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antibiotic prophylaxis with trimethoprim-sulfamethoxasole
Trial: 6352004
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2) every 3 weeks
Trial: 6352004
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin
Trial: 31851158
Drug: Trimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodal therapy (TMT) consisting of maximal transurethral resection of the bladder tumor followed by concurrent radiosensitizing chemotherapy and radiotherapy
Trial: 31851158
Drug: Bladder-sparing therapies
RxNorm normalized name: Sus scrofa urinary bladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder-sparing therapies (including partial cystectomy, radiation monotherapy, and radical transurethral resection)
Trial: 26907659
Drug: Twice-daily low-molecular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily low-molecular weight heparin
Trial: 26907659
Drug: Platelet transfusion
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet transfusion to maintain platelet count >50×10/L
Trial: 25025601
Drug: Iyengar yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iyengar yoga (IY) program, 6-week duration, twice per week
Trial: 22008735
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg) + Gaboxadol (10 mg)
Trial: 22008735
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg) + Gaboxadol (5 mg)
Trial: 17157479
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 4 mg dexamethasone (Dexason) into the internal pterygoid muscle
Trial: 17157479
Drug: LPL irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LPL irradiation supplemented by systemic dexamethasone (4 mg i.m. in deltoid region, followed by 4 mg intraorally 6h postoperatively)
Trial: 11053821
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml aprotinin (Trasylol, Bayer AG)
Trial: 11053821
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml physiological saline solution
Trial: 9363289
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg per day)
Trial: 6397218
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 mg, three times daily
Trial: 6397218
Drug: Nicardipine slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine slow release 30 mg, twice daily
Trial: 24396060
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (2 μg kg(‐1) min(‐1))
Trial: 19129422
Drug: AZD7009 30-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7009 30-minute 3.25 mg/min
Trial: 19129422
Drug: AZD7009 15-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7009 15-minute 3.25 mg/min
Trial: 19129422
Drug: AZD7009 15-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7009 15-minute 4.4 mg/min
Trial: 19129422
Drug: AZD7009 30-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7009 30-minute 3.25 mg/min (AF episodes <=30 days)
Trial: 19129422
Drug: AZD7009 best-dose
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7009 best-dose group
Trial: 15734231
Drug: Active 2mg
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active 2mg nicotine lozenge
Trial: 12190711
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention program including collaborative treatment plan, monthly telephone monitoring by a nurse care manager, feedback of monitoring results, algorithm-based medication recommendations, outreach and care coordination, structured psychoeducational group program (Life Goals Program).
Trial: 7814823
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg oral dose)
Trial: 7814823
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg i.v. administered 5 days before baseline)
Trial: 2815976
Drug: Purified chick
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified chick embryo cell (PCEC) rabies vaccine
Trial: 2815976
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell rabies vaccine (HDCV)
Trial: 1090337
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 mu g)
Trial: 1090337
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (40 mu g)
Trial: 1090337
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salbutamol and ipratropium bromide
Trial: 27189595
Drug: FENO-based asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENO-based asthma management (adjusted inhaled corticosteroid dose based on FENO levels)
Trial: 27189595
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (one clinical assessment of asthma, self-management education, treatment changes by general practitioner)
Trial: 21320109
Drug: Carisbamate 800
RxNorm normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisbamate 800 mg/day
Trial: 23692321
Drug: Carisbamate 1200
RxNorm normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisbamate 1200 mg/day
Trial: 21968546
Drug: Flow rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flow rate adjusted to heart rate (Group 1: dosage/16)
Trial: 17475962
Drug: (18)F-FDG PET
RxNorm normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (18)F-FDG PET studies at 1 and 3 weeks after chemotherapy initiation
Trial: 12548530
Drug: Prednisone (low-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (low-dose, alternate-day)